A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy

被引：92

作者：

Cameron, D. William ^{[1
]}

da Silva, Barbara A. ^{[3
]}

Arribas, Jose R. ^{[6
]}

Myers, Robert A. ^{[4
]}

Bellos, Nicholaos C. ^{[5
]}

Gilmore, Norbert ^{[2
]}

King, Martin S. ^{[3
]}

Bernstein, Barry M. ^{[3
]}

Brun, Scott C. ^{[3
]}

Hanna, George J. ^{[3
]}

机构：

[1] Univ Ottawa, Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada

[2] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[3] Abbott Labs, Abbott Pk, IL 60064 USA

[4] Body Posit Inc, Phoenix, AZ USA

[5] SW Infect Dis Associates, Dallas, TX USA

[6] Hosp La Paz, Madrid, Spain

来源：

JOURNAL OF INFECTIOUS DISEASES | 2008年 / 198卷 / 02期

关键词：

D O I：

10.1086/589622

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antiretroviral-naive HIV-1-infected volunteers received zidovudine/lamivudine plus either lopinavir/ritonavir (n = 104) or efavirenz (n = 51). Lopinavir/ritonavir-treated subjects demonstrating 3 consecutive monthly HIV-1 RNA levels <50 copies/mL started lopinavir/ritonavir monotherapy. In previous-failure = failure analysis, 48% (lopinavir/ritonavir) and 61% (efavirenz) maintained HIV-1 RNA at <50 copies/mL through week 96, (P = .17; 95% confidence interval [CI] for the difference, -29% to 4%); in noncompletion = failure analysis, 60% (lopinavir/ritonavir) and 63% (efavirenz) maintained HIV-1 RNA at < 50 copies/ mL at week 96 (P = .73; 95% CI for the difference, -19% to 13%). Significant sparing of peripheral lipoatrophy was noted in the lopinavir/ritonavir simplification strategy. This study has provided important information for future studies using treatment simplified to lopinavir/ritonavir monotherapy.

引用

页码：234 / 240

页数：7

共 14 条

[1] Lopinavir/ritonavir as single-drug therapy for maintenance of HlV-1 viral suppression -: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study)
Arribas, JR
Pulido, F
Delgado, R
Lorenzo, A
Miralles, P
Arranz, A
González-García, JJ
Cepeda, C
Hervás, R
Paño, JR
Gaya, F
Carcas, A
Montes, ML
Costa, JR
Peña, JM
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) : 280 - 287
[2] Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients
Campo, RE
Lalanne, R
Tanner, TJ
Jayaweera, DT
Rodriguez, AE
Fontaine, L
Kolber, MA
[J]. AIDS, 2005, 19 (04) : 447 - 449
[3] Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
Delfraissy, Jean-Fran Ois
Flandre, Philippe
Delaugerre, Constance
Ghosn, Jade
Horban, Andrzej
Girard, Pierre-Marie
Norton, Michael
Rouzioux, Christine
Taburet, Anne-Marie
Cohen-Codar, Isabelle
Van, Philippe Ngo
Chauvin, Jean-Pierre
[J]. AIDS, 2008, 22 (03) : 385 - 393
[4] GATHE JC, SINGLE AGENT THERAPY
[5] GOELZ J, SINGLE AGENT HAART L
[6] HAUBRICH RH, 2007, 14 C RETR OPP INF LO
[7] The metabolic effects of lopinavir/ritonavir in HIV- negative men
Lee, GA
Seneviratne, T
Noor, MA
Lo, JC
Schwarzb, JM
Aweeka, FT
Mulligan, K
Schambelan, M
Grunfeld, C
[J]. AIDS, 2004, 18 (04) : 641 - 649
[8] HOMEOSTASIS MODEL ASSESSMENT - INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA-GLUCOSE AND INSULIN CONCENTRATIONS IN MAN
MATTHEWS, DR
HOSKER, JP
RUDENSKI, AS
NAYLOR, BA
TREACHER, DF
TURNER, RC
[J]. DIABETOLOGIA, 1985, 28 (07) : 412 - 419
[9] Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice
Molto, Jose
Santos, Jose Ramon
Negredo, Eugenia
Miranda, Cristina
Videla, Sebastia
Clotet, Bonaventura
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (02) : 436 - 439
[10] Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity:: demonstrable differences in vitro and clinically
Noor, Mustafa A.
Flint, Oliver P.
Maa, Jen-Fue
Parker, Rex A.
[J]. AIDS, 2006, 20 (14) : 1813 - 1821

← 1 2 →